Based on the available data, combining agents that inhibit PD-L1 expression and enhance anti-tumor immune responses—such as NRP2 or RelB inhibitors—with existing regimens may further improve therapeutic efficacy in prostate cancer. The gene discussed is CD274; the disease is neoplasm.